Aug 6, 2007
Materia, Inc. was pleased to provide attendees of the 17th International Symposium on Olefin Metathesis and Related Chemistry (ISOM XVII) with the opportunity to visit their facilities in Pasadena, California. Over 60 ISOM XVII attendees toured Materia’s labs and were able to see first hand metathesis catalyst production processes and industry applications of the technology. Read more
PASADENA, CA. – (BusinessWire) – June 20, 2007. Materia, Inc., a catalyst technology company, announced today the licensing of its metathesis platform to Eisai Co., Ltd., a leading Japanese pharmaceutical company, for use in drug discovery and development. The non-exclusive license agreement provides rights to discover, develop, and patent pharmaceutical compounds and related processes using the Company’s catalysts and associated intellectual property. Read more
PASADENA, CA. and CHAPEL-EN-LE-FRITH, UK. – (BusinessWire) – March 1, 2007. Materia, Inc. and Peakdale Molecular Ltd. announced today their collaboration to offer metathesis-based scaffolds for the pharmaceutical industry. Under the agreement, Peakdale has acquired non-exclusive rights to practice Materia’s metathesis intellectual property portfolio for the design, development, and sale of research quantities of the scaffolds. The partners will jointly identify target compounds, while Peakdale will be primarily responsible for the compounds’ development, production, and initial distribution. Read more
PASADENA, CA. – (BusinessWire) – February 12, 2007. Materia, Inc., a catalyst technology company, announced today the licensing of its metathesis platform to Aileron Therapeutics, an emerging biopharmaceutical company, for use in the discovery and development of peptide therapeutics directed at intracellular protein-protein interaction targets. As consideration for the license, Materia will receive license fees, milestone payments, and royalties. Read more